Abstract. Background: The group IIA secretory phospholipase A 2 gene, Pla2g2a, confers resistance to intestinal tumorigenesis in the Apc Min/+ mouse model. However, it is unclear how Pla2g2a exerts its tumor-suppressive effects and whether its mode of action depends on Apc-germline mutations.
Introduction
Treatment of rodents with the DNA alkylating carcinogen, azoxymethane (AOM), induces colon tumors that exhibit a range of molecular alterations that is similar to that observed in human colorectal cancer [4, 19, 22, 32, 33, 36, 56, 64, 67] . Interestingly, inbred strains of mice used in AOM studies demonstrate marked differ-ences in susceptibility to AOM-induced tumorigenesis [11, 58, 66] . For example, A/J mice are highly sensitive to AOM-induced neoplasia while AKR/J mice are highly resistant. In the Apc Min/+ mouse, a genetic model for colorectal cancer, a number of genetic modifiers have been identified. An example is the Mom1 (Modifier of Min-1) locus [21] , a complex of genes on distal chromosome four that includes the Pla2g2a gene, which encodes for a secretory phospholipase that is naturally mutant in the C57BL/6 mouse strain [48] . Strains of mice that carry the mutant Pla2g2a allele develop a severe Apc Min/+ phenotype while strains that carry the wildtype Pla2g2a allele demonstrate resistance to intestinal tumorigenesis [30] . Genetic evidence for Pla2g2a's function as a suppressor of tumorigenesis was demonstrated by the reduction in tumors observed in C57BL/6 Apc Min/+ mice carrying a wildtype Pla2g2a transgene derived from the AKR strain [17] . The Pla2g2a tumor resistance phenotype is strongest in the large intestine [16] .
Transcription of the wild-type Pla2g2a transgene is driven by its endogenous promoter sequences, and spatial distribution of its expression is similar to expression of the endogenous Pla2g2a gene, i.e. by Paneth cells in the small intestine and by goblet cells in the large intestine [16, 17, 50] . The mechanisms underlying Pla2g2a's suppression of tumor development in the Apc Min/+ mouse are not clear. Two explanations that have been proposed are: (1) Pla2g2a's bactericidal functions as a secreted molecule that may help manage the flora in the intestinal crypt lumen, thereby limiting inflammation and maintaining gut homeostasis, and (2) via the production of fatty acids and its derivatives like prostaglandins with potent signaling activity. While Pla2g2a's antimicrobial activity may indeed be shown to play a significant role in its tumor resistance, recent work has also shown that Pla2g2a is involved in complex signaling pathways that includes the Wnt/β-catenin cascade [3, 23, 26, 62] .
In the current study we extended previous work by testing whether expression of a wildtype AKR-derived Pla2g2a transgene in C57BL/6J mice could prevent tumor development in the AOM model of intestinal tumorigenesis. Moreover, the effects of Pla2g2a expression on normal colon were investigated by comparing genome-wide gene expression profiles of distal colon tissues obtained from C57BL/6J mice that expressed either mutant or wildtype copies of the Pla2g2a gene. Overall, we found that expression of Pla2g2a provided strong resistance to AOM-induced colon tumorigenesis, in both genders and at 8 and 12 months of age.
In addition, we observed AOM-induction of tumors in the small intestine, principally in the duodenum, a phenotype that was also attenuated by the expression of Pla2g2a. Expression analysis identified Pla2g2a target genes that modulate cell signaling, transactivation, apoptosis, intracellular trafficking, inflammation, and intestinal metabolism were identified that suggest mechanisms underlying Pla2g2a's tumor resistance. Pathway analysis by Gene Set Enrichment Analysis (GSEA) revealed suppression of interferon-induced genes as a potentially key effect of Pla2g2a, indicating that modulation of gut immune homeostasis may underlie Pla2g2a's action.
Materials and methods

Mice
C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, ME). C57BL/6J-Pla2g2a-Tg mice [16] were obtained from a colony maintained at the University of Minnesota Medical School. C57BL/6J mice were crossed to C57BL/6J-Pla2g2a-Tg mice and all AOM test mice were littermates generated from this cross. Mice used for gene expression analysis also came from the same colony. All mice were housed and bred at the University of Minnesota Medical School Duluth Animal Services Facility (AALAC accredited) and all mouse experiments followed a protocol approved by the University of Minnesota Institutional Animal Care and Use Committee. Mice were housed in micro-isolator cages that were changed in a laminar flow hood following a customary protocol to prevent pathogen transfer. Sentinel mice caged on the same racks as experimental mice tested negative for a panel of common pathogens during the entire period of the study. All mice were fed food (Purina 5001 Rodent Chow) and tap water ad libitum. All mice were monitored daily for signs of distress and sacrificed when either distressed or moribund. Test mice were sacrificed at 240 and 360 days.
Azoxymethane treatment
AOM was obtained from Sigma-Aldrich (St. Louis, MO) in 100 mg vials, diluted in saline (0.9% NaCl) at a concentration of 1.25 mg/ml, and aliquots were stored frozen until use. Mice, starting at 45 days of age, were administered 10 mg AOM/kg body weight by intraperitoneal injection once per week for 6 consecutive weeks. All mice were treated with AOM blind to genotype.
Genotyping
DNA was isolated from tail snips using a Qiagen DNA Easy kit. The genotype of the Pla2g2a locus was determined by PCR assay as previously described [16] . PCR was performed on an Applied Biosystems GeneAmp 9700 Thermal Cycler.
Tumor analysis
All mice were sacrificed by CO 2 asphyxiation. The entire intestinal tract was removed, washed in 1X PBS and cut into five sections consisting of the large intestine (including colon and cecum) and four equal length sections of the small intestine. Each section was cut longitudinally and fixed flat overnight in 10% buffered neutral formalin between bibulous paper and 3-ply paper towel. Tissues were then transferred to 70% ethanol, further cleaned and stored in paraffinsealed vials prior to scoring. Tumors were independently scored by two observers (L.K.B., R.T.C.) blind to the genotype of the sample using a Nikon SMZ1000 dissecting microscope at 10× magnification.
Histopathology
Histopathological analysis of tumors and adjoining normal tissue was performed on formalin-fixed tissues obtained from male and female mice from both the 240 and 360 day classes of C57BL/6J mice that were either positive or negative for the Pla2g2a transgene. Multiple H&E sections were obtained from tumors from the colon and duodenum. All tissues were analyzed blind to the genotype of the samples by an A.C.V.P.-certified veterinary pathologist (M.G.O'S.) from the University of Minnesota Cancer Core Histopathology Shared Resources facility and using the standardized nomenclature of the 2003 Consensus Report and Recommendations for pathology of mouse models of intestinal cancer as published [12] .
Immunohistochemistry
4 µm formalin-fixed, paraffin-embedded sections of small intestinal tumors were deparaffinized and rehydrated, followed by antigen retrieval using 10 mM Citrate buffer pH 6.0 in the Biocare Decloaking Chamber (electric pressure cooker) (Biocare, Walnut Creek, CA). Immunohistochemistry for β-catenin was performed on a Dako Autostainer (Dako, Carpinteria, CA) using a goat anti-human β-catenin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) as primary antibody (after blocking endogenous peroxidase and application of a protein block), with detection by a biotinylated donkey anti-goat antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) and streptavidin-linked horse radish peroxidase (Dako) using diaminobenzidine (Dako) as the chromogen. Mayer's Hematoxylin (Dako) was used as the counterstain. Small intestinal adenomas from Apc Min/+ mice were used as a positive control tissue, and for negative control slides the primary antibody was substituted with Super Sensitive Goat Negative Serum (Biogenex, San Ramon, CA).
Tumor statistical analysis
Two-sided P values for tumor counts were determined by use of Student's t-test comparing gender and age-matched classes produced in the same genetic crosses.
RNA extraction and quality control
The colon of mice was removed, cut longitudinally, cleaned in PBS and stored in Qiagen RNA Later (Valencia, CA). Using a polytron homogenizer, about 1 cm of tissue was homogenized in TRIzol reagent (Invitrogen, Paisley, UK). Total RNA was isolated following the manufacturer's protocol. RNA concentrations were measured with a Nanodrop spectrophotometer (ND-1000, NanoDrop Technologies; Wilmington, DE) and treated with RNase-Free DNase (Promega, Madison, WI). The quality of RNA preparations was assessed with a lab-on-a-chip 2100 Bioanalyzer (Agilent Technologies, Wilmington, DE). All samples used for microarray analysis had an RNA integrity number (RIN value) of 7 or higher, following the manufacturer's recommendations.
Oligonucleotide microarray and data analysis
Two-color microarray-based gene expression analysis was carried out using Agilent 4 × 44K whole mouse genome microarrays (G4122F, Agilent Technologies, Wilmington, DE). This array includes more than 41,000 mouse genes and transcripts. Per sample, 500 ng of RNA was spiked, labeled, amplified, and hybridized using Agilent reagents, according to Agilent Gene Expression oligo microarrays protocol (version 5.0.1). For each group (transgenic and nontransgenic) half of the samples were labeled with Cy3 and half of the samples with Cy5, to prevent bias of the data due to labeling with these fluorescent dyes. Arrays were scanned using an Agilent Microarray Scanner, and the intensity of fluorescent images was quantified using Agilent Feature Extraction software (version 9.1.3). Pre-processing of data, quality checks, and significance analysis were all performed using the RBioconductor [28] package using 'limma' [63] . Differential expression of genes was quantified by the moderated t-statistic. Raw P -values were adjusted for multiple testing by using the Benjamini-Hochberg [9] false discovery rate (FDR) correction. Genes with adjusted P -value smaller or equal to 0.1 were declared to be significant. A detailed description of the microarray data analysis is provided in the Supplementary Methods. The analysis R-scripts are available upon request from the authors (M.A. van de Wiel). Following this protocol, RNA expression profiles from the colon of 6 C57BL/6J-Pla2g2a-Tg mice (3 females, 3 males) and 4 C57Bl/6J mice (2 females, 2 males) were analyzed, and differentially expressed genes, allowing for gender, were identified. Functional classification of these genes and pathway analysis were carried out using Ingenuity Pathways Analysis software (www.ingenuity.com), provided through the University of Minnesota Supercomputing Institute. In addition, GSEA was used as a computational method to identify sets of genes with coordinate differences in gene expression (GSEA v2.0, http://www.broad. mit.edu/gsea/) [54, 65] . Gene sets analyzed were obtained from the Molecular Signatures Database (MSigDB_v2.5, http://www.broad.mit.edu/gsea/ msigdb/index.jsp) and comprised curated gene sets, motif gene sets, and Gene Ontology (GO) gene sets, i.e. collections c2, c3 and c5. Default settings were used, except for 'Collapse dataset to gene symbols' (set to 'false'), 'Permutation type' (set to 'gene_set'), and the 'Max size' of gene sets (set to '1500'). Gene sets with a family-wise error rate FWER < 0.05, which is used as a conservative correction factor that aims to exclude even a single false-positive gene set [65] , were considered significant.
Quantitative real time PCR
RNA was made as described above or with RNAeasy Plus Mini Kit with gDNA Eliminator (Qiagen). cDNA was synthesized using the GeneAmp Gold RNA PCR Core Kit (Applied Biosystems). SYBR green real time PCR assays employed the Power SYBR Green PCR Master Mix (Applied Biosystems). The expression level of each gene was determined in triplicate by real time PCR in the 7900HT Sequence Detection System (Applied Biosystems). After PCR amplification in the thermocycler, a C t value was determined for each sample. The relative amount of mRNA for each gene was determined by comparing the C t value of the control and treated samples after normalization with the GAPDH internal control gene. All real time PCR work was performed by ACGT Inc. (Wheeling, IL, USA) except for Pla2g2a, whose overexpression in C57BL/6J-Pla2g2a-Tg mice compared to C57BL/6J mice was previously determined by ACTG Inc. on a Muc2-deficient background [25] , and now determined by our lab using the qRT-PCR protocol described by Carvalho et al. [14] . Primer sequences are as follows: Nudt-F GTGCACAGCGA GACCAAGTA; Nudt-R TTTGCAAAGTTGCTGGT GAG; Aldh2-F TGTCAGGGAGTGGCAGGG; Aldh2-R CGGGCTG AGGAAGCAGG; Klk7-F TGTGCTCGGATGTGAA GCTCATCT; Klk7-R GTCACCATTGCACGTGTTG GTCTT; Mier2-F GTCAGACCCCATCTCTGAGC; Mier2-R TCTTCTTCCCCAGAAAGCAA; Rab5c-F ACGGGCTAAGAATTGGGTGAAGGA; Rab5c-R TCTGCATAGGCTTGTGCTTCCTGA; Map3k10-F AGTTCCACTTTGCAGAAGGAGCGA; Map3k10-R CATCTGCCTCCGCAAATTCTTCCA; Adam11-F GTGCACAGCGAGACCAAGTA; Adam11-R TTTG CAAAGTTGCTGGTGAG; Yap1-F GCGCCTATGAT TGGCCAG; Yap1-R GATAAGGTCAGAGAGCACT GTCAGG; Ercc2-F AAGCCCCTCAGGTTCTGTGC TGAA; Ercc2-R CTTGGCGTAAGTGCTGACGAG AGT; Ccr3-F CGTTCCCAGGTGGTGGAC; Ccr3-R CCTCCTACAACACTTGTGACATCC; Nfkbil1-F AC GGAAGGAAGCAAGGTCG; Nfkbil1-R GGTTAGA GCCTCCCCCACC; EphB2-F AGCAACCTGGTGT GTAAGGTGTCT; EphB2-R ATGACGATGCCATAG CTCCACACA; Dock8-F ACTGTGCAGCCGATGAG GAAGTTA; Dock8-R TTGAACCTGGCGCATCAC TATTGC; Pla2g2a-F CACCACTCCACTGCCTTGA AT; Pla2g2a-R GCAGGAAGTTGGATGCCAA; Sema7a-F TTCTAAGTACCATTACCAGAAAGTGG TC; Sema7a-R CCCTGATTCCACCACCTTGT.
Results
Effect of Pla2g2a on AOM-induced colon tumors
Similar to the phenotype observed in the Apc Min/+ mouse model [16, 17] , expression of Pla2g2a provided strong resistance to colon tumorigenesis in mice treated with AOM (Table 1) . At 240 days male C57BL/6J mice developed 1.6 colon tumors on average with a tumor incidence of 50%. Strikingly, none of the 19 male C57BL/6J-Pla2g2a-Tg mice treated with AOM developed a colon tumor. In female mice, there was a 7-fold reduction in colon tumors at 240 days with female C57BL/6J mice developing a mean of 1.4 tumors (46% tumor incidence), compared with 0.2 tumors (21% tumor incidence) in C57BL/6J-Pla2g2a-Tg mice. At 360 days, there was a similar pattern of tumor resistance, although male C57BL/6J-Pla2g2a-Tg mice did start to develop some colon tumors at 360 days (0.4 tumors vs. 1.3 tumors in non-transgenics). In female mice there was a similar reduction in tumors at 360 days (1.8 tumors in C57BL/6J mice vs. 0.3 tumors in C57BL/6J-Pla2g2a-Tg mice). We examined the size of colon tumors at 240 and 360 days but did not observe any noticeable differences in sizes (data not shown). We also investigated whether expression of Pla2g2a modulated the progression of tumors. We examined 19 colon tumors from C57BL/6J mice (11 tumors from 240 days and 8 tumors from 360 days) and 12 tumors from C57BL/6J-Pla2g2a-Tg mice (6 tumors at 240 days and 6 tumors from 360 days). Only 1 neoplasm (out of the total of 37) was judged to be an adenocarcinoma and this came from the C57BL/6J nontransgenic group.
Development of AOM-induced duodenal tumors
In addition to induction of colon tumorigenesis AOM also induced the formation of tumors in the small intestine, principally in the duodenum (Fig. 1, panels A  and B) . These tumors were predominantly small sessile or broad based adenomas, with some lesions appearing somewhat pedunculated; dysplastic epithelium was arranged predominantly in branching tubules. Some tumors also had a central flattened area giving a cup-like appearance on cross section. Histopathological analysis of 24 of these tumors (18 from C57BL/6J mice and 6 from Pla2g2a transgenics) did not find any tumors that were invasive. To investigate involvement of the Wnt-signaling pathway in AOM-induced small intestinal tumors we evaluated the expression of β-catenin by immunohistochemistry. We found increased expression of β-catenin in the tumors, as reflected in increased intensity of stain within epithelial cells of the tumors (Fig. 1, panels C and D) ; also notable was increased expression of β-catenin in the nuclei of tumor cells (Fig. 1, panel D) .
Similar to its effect in the colon expression of Pla2g2a conferred resistance to tumorigenesis in the small intestine, although the reduction in tumor numbers was smaller at 360 days. At 240 days, male C57BL/6J mice developed 0.8 tumors on average in the small intestine with a tumor incidence of 46%, compared with 0.05 tumors (just 1 tumor in 19 mice) in the male C57BL/6J-Pla2g2a-Tg mice. In female mice at 240 days the averages were 1.5 tumors (36% incidence) in C57BL/6J mice compared with 0.1 tumors (9% incidence) in the C57BL/6J-Pla2g2a-Tg mice. However, at 360 days the C57BL/6J-Pla2g2a-Tg mice developed a few more tumors than at 240 days. C57BL/6J males developed 0.8 tumors (62% incidence) compared with 0.2 tumors (22% incidence) in C57BL/6J-Pla2g2a-Tg mice. For female mice at 360 days the mean tumor averages were 0.8 (62% incidence) for C57BL/6J mice and 0.3 (18% incidence) for the C57BL/6J-Pla2g2a-Tg mice. Tumor sizes in the small intestine were not significantly different between classes (data not shown). 
Identification of Pla2g2a target genes and pathways
To investigate the genetic pathways underlying the suppressive effects of Pla2g2a on carcinogenesis we conducted microarray expression studies using gendermatched distal normal colon tissues obtained from colony littermates that were not treated with AOM. Non-pathologic colon tissue was chosen because we hypothesized that the effects of Pla2g2a influence the colon microenvironment, thereby generating conditions that attenuate tumor development. The mice were sacrificed at 100 days of age. This age was chosen because it provided a snapshot of gene expression at the age where the tumor induction protocol is completed in AOM-treated littermates, hence a timepoint where the gene expression profiles are most likely to reveal their differential effects on tumor development. We found that Pla2g2a significantly altered expression levels of 420 transcripts, representing 382 genes (∼1% of the >41,000 genes and transcripts on the Agilent microarray), based on use of the adjusted P value statistic. A complete list of differentially expressed genes, grouped by functional classification is found in Suppl. Note: qRT-PCR -quantitative reverse transcriptase-polymerase chain reaction.
were identified) was confirmed by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) ( Table 2) . Changes in biological processes are often accompanied by coordinate variation in expression of sets of genes. We applied GSEA to identify gene sets that were differentially expressed in normal colon from C57BL/6J-Pla2g2a-Tg mice compared to normal colon of C57BL/6J mice. Pre-defined gene sets were obtained from the Molecular Signatures Database (MSigDB_v2.5) and comprised curated gene sets, motif gene sets, and gene ontology (GO) gene sets. Using the family-wise error rate as a conservative correction factor (FWER < 0.05), a total of 24 gene sets were identified that exhibited significant differential expression (Table 3) . Notably, the most common biological pathways identified concerned the expression of interferon (IFN)-induced genes. Gene sets #1-12 all share genes that are induced by IFNα [10, 13, 20, 46, 59, 68, 73] , while gene set #13 involves genes induced by IFNγ [61] . The important role of IFN-induced genes was further underscored by identification of the Interferon Regulatory Factor-2 (IRF2) motif (gene set #21), indicative of genes with an IRF2 recognition site in their promoter region within 2 kb of the gene transcription start site. Moreover, differences were observed for genes induced by TNFα (gene sets #14 and 15) [47, 61] , and the GO gene sets for chemokines and chemokine receptor binding (gene sets #22-24). In addition, significant differences were observed related to epithelial to mesenchyme transition (EMT; gene sets #16 and 17) [40] , and to proliferation/cell cycle (gene sets #18-20) [18, 29, 71] , the latter all sharing genes involved in spindle formation.
Discussion
In our current study we extended previous work using the Apc Min/+ mouse model by asking whether expression of Pla2g2a could prevent the development of colon tumors in the AOM model. We found that Pla2g2a provided strong tumor resistance, virtually eliminating AOM-induced tumors at 240 days. This was true in both male (0 tumors in 19 mice) and female mice (6 tumors in 34 mice), and in mice aged to both 240 and 360 days. A novel observation (in mice), was our observation of tumors in the small intestine at a frequency approaching their incidence and multiplicity in the colon. These tumors are primarily adenomas that form in the duodenum. Immunohistochemical analysis using a polyclonal antibody against β-catenin showed increased expression of β-catenin in these tumors. Previous AOM studies in mice failed to observe these tumors, possibly due to strain differences. C57BL/6 mice are relatively resistant to AOM-induced colon tumors and thus many previous studies have used tumor sensitive strains such as A/J. It is known that C57BL/6 mice are susceptible to tumors in the small intestine in Apc-deficient models such as the Apc Min/+ mouse and that the related strain B10.O20/Dem carries the susceptible allele of ssic1 [24] , a tumor susceptibility locus for ENU-induced small intestinal cancer for which Pla2g2a is a candidate gene. Thus C57BL/6 may carry susceptibility alleles for AOM-induced tumor formation in the small intestine. Our data support Pla2g2a being one potential AOM susceptibility gene for carcinogen-induced small intestinal cancer.
In parallel to the AOM study we conducted microarray expression analysis of non-pathologic colon of untreated littermates of both genotypes and both genders, to examine the effects of Pla2g2a expression on the colon microenvironment. In all we found 382 genes that are differentially expressed in Pla2g2a transgenic mice compared with C57BL/6J non-transgenic littermates. Pla2g2a target genes represent a broad range of molecules that are involved in induction of apoptosis, inflammation and immune response, transactivation and cell signaling, intracellular trafficking and intestinal lipid and energy metabolism. Of these groups, Table 3 Gene sets that are more highly expressed in colon of C57BL/6J mice compared to colon of C57BL/6J-Pla2g2a-Tg mice [37] , Bax [69] , Klhl12 [5] and Stk4 [53] . Similarly, Pla2g2a down regulated a group of genes that may be oncogenic, including Nrg1 [2] and Twist1 [70] . Pla2g2a is a Wnt/β-catenin target gene that is expressed in the secretory cell lineage, by the Paneth and goblet cells in the small intestine and by the goblet cells in the large intestine. Our microarray data suggest that Pla2g2a may function as a link between several of the canonical signaling pathways in the GI tract. For example, Pla2g2a alters the expression of a number of genes involved (directly or indirectly) in both the Wnt/β-catenin (Mdfi, Klhl12, Fut8, Vangl2, Fzd8, EphB2, Fus, Ptk7, Parp1, Rab5c, Sost) and the Notch (Gja1, Mapk8ip1, Sh3d19, Cdx2, Ifng, Stat1, Runx1, Lhx1, Yap1, Smo, Ncor2) signaling pathways, involved in maintenance of the stem cell compartment and in lineage specification in the mammalian gut. Pla2g2a and EphB2 have been linked in several reports over the past three years. EphB2 is a member of the Eph family of receptor tyrosine kinases and it is also a β-catenin target gene [8] . EphB2 expression is lost in some advanced human cancers but is also upregulated (like Pla2g2a) in some early stage intestinal adenomas in humans. Pla2g2a and EphB2 are co-regulated in both human colorectal and gastric cancers [3, 44] , Pla2g2a and EphB2 are both up regulated in mouse intestinal adenomas [57, 62] , and EphB2, like Pla2g2a, has also been demonstrated to be a potent tumor suppressor in mouse GI cancer models [7, 15] . In gastric cancers, Aggarwal and colleagues in the group of Patrick Tan have described a set of 10 genes that reside in the "Pla2g2a neighborhood" [3] , that include EphB2 and Ctnnb1 (β-catenin). Two other genes in the neighborhood are Lmo4 and Cpa2, both differentially expressed in Pla2g2a transgenic colon. Lmo4 (Lim homeobox gene 4), which is up regulated by Pla2g2a, has been reported to induce expression of BMP7, part of the TGFβ signaling pathway. More recent work by the same group of investigators has shown that in human gastric cancer PLA2G2A acts downstream of β-catenin and inhibits gastric cancer metastasis via down regulation of S100A4, a potent pro-metastatic and proinflammatory factor [26] .
We aimed to further exploit the biological processes that are influenced by Pla2g2a in the colon by pathway analysis, using GSEA. In total, 24 gene sets were identified that exhibited significant differential expression (Table 3 ). Due to overlapping composition of several of these gene sets, the number of biological processes they point to is less diverse. Most of the curated gene sets revealed enrichment for differential expression of genes that can be induced by IFNα [10, 13, 20, 46, 59, 68, 73] . Other curated gene sets pointed to induction of gene expression by IFNγ and/or TNFα [47, 61] . These findings are further supported by identification of the IRF2 (Interferon Regulatory Factor-2) motif gene set. The GO-derived gene sets all point towards chemokine signaling, which is also indicative for leukocyte migration and immune regulation. Because all of these pathways were higher expressed by normal colon of C57BL/6J mice compared to colon of C57BL/6J-Pla2g2a-Tg mice, collectively they indicate that expression of Pla2g2a attenuates basal levels of immune activation. In addition, identification of two largely overlapping gene sets reflecting epithelial to mesenchyme transition (EMT), a profile that is based on exposure of epithelial cells to TGFβ [40] , provided additional support for the notion that Pla2g2a may suppress metastatic behavior [26] .
Quantitative RT-PCR validation analysis of a subset of the most significant genes identified in the arrays, chosen from different functional groups, confirmed the pathway analysis. Genes involved in inflammatory responses (and further linked to cytokine, chemokine, NF-κB and interferon signaling) included Adam11 [6] , Nfkbil1 [31, 60] , Sema7a [38] , Map3k10 [41, 42] and Ccr3 [1, 35] . Another group of genes confirmed by qRT-PCR were either directly involved in DNA repair such as Ercc2 [72] , or more indirectly in protection against cellular damage, such as Aldh2 [27, 51, 55] and Nudt15 [52] . Several other genes confirmed by qRT-PCR are part of canonical signaling pathways in the GI tract such as Wnt/β-catenin (EphB2 [8] , Rab5c); Notch (Yap1 [43, 45] ), and TGFβ, Hedgehog and EMT (Map3k10 [41, 42] ). Notably, several of these qRT-PCR genes have previously been linked to resistance to human colorectal cancer, including Ercc2, Aldh2 and EphB2, and other genes on the list such as Adam11 and Dock8 have been reported to be down regulated in other types of cancers, such as in breast and lung.
Considered together, expression of Pla2g2a attenuates tumor development in the small and large intestine independent of Apc-germline mutations. This finding is further supported by the observation that Pla2g2a (directly or indirectly) influences expression of numerous genes in normal (non-pathologic) colon, including genes involved in the Wnt/β-catenin, Notch, and possibly the TGFβ and Hedgehog pathways. These data suggest that modulation of these key-signaling pathways, involved in proliferation and differentiation of (colon crypt) stem cells, is one mechanism in which Pla2g2a attenuates tumor development. GSEA pathway analysis supports the notion that Pla2g2a contributes to maintenance of gut immune homeostasis, suggesting that prevention of chronic inflammation, mediated by inhibition of interferons, NF-κB and TNFα activity, is another mechanism in which it reduces tumor incidence [34, 39, 49] . However, what cells initially respond to Pla2g2a and how their effects shape the colon microenvironment remains to be elucidated.
